Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with fast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cost Eff Resour Alloc
Main Authors: McEwan, Phil, Webster, Samantha, Ward, Thomas, Brenner, Michael, Kalsekar, Anupama, Yuan, Yong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521139/
https://ncbi.nlm.nih.gov/pubmed/28736505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0077-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados